Lipid profiling in amyotrophic lateral sclerosis

Takeaway

  • Systemic hypermetabolism could be a modifier of disease progression in patients with amyotrophic lateral sclerosis (ALS). Plasma lipidomic analysis could potentially be used to stratify patients with ALS.

Why this matters

  • ALS is a clinically heterogeneous neurodegenerative disease. It is known that metabolic changes, specifically hypermetabolism, have a significant bearing on prognosis in patients with ALS.

  • The results of lipid profiling using liquid chromatography with mass spectrometry (LC/MS) have been published for select ALS cases. Lipid profiles have either been performed for the cerebrospinal fluid (CFS) or plasma, but never in the same patient.